A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.
Peter Benko, PharmD Candidate Class of 2021, the University of Connecticut
Advertisement
Articles by Peter Benko, PharmD Candidate Class of 2021, the University of Connecticut
Advertisement
Latest Updated Articles
Dapagliflozin: Benefits in Heart Failure Patients With and Without DiabetesPublished: December 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA, HHS Move to Accelerate Biosimilar Approvals
2
Accelerated Approval of Cancer Drugs: Benefit or Burden?
3
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
4
Pharmacists Lead the Way in Evolving CAR T-Cell and Bispecific Antibody Therapy Management
5
